Phase 3 acute bacterial skin and skin-structure infection (ABSSSI) studies SOLO I and SOLO II included 405 patients with confirmed MRSA.
Clinical response rates by pathogen were similar for oritavancin and vancomycin.
Clinical response in Staphylococcus  aureus patients was not impacted by spa type or pvl gene.
Oritavancin exhibited potent in vitro activity against all baseline pathogens.
Oritavancin provides a single-dose alternative to multidose vancomycin for ABSSSI.